{
    "clinical_study": {
        "@rank": "75758", 
        "brief_summary": {
            "textblock": "To further evaluate the safety of megestrol acetate (Megace) oral suspension in the\n      treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2\n      doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12\n      and 24 weeks."
        }, 
        "brief_title": "The Safety and Effectiveness of Megace in HIV-Infected Women", 
        "condition": [
            "Anorexia", 
            "Cachexia", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Anorexia", 
                "Cachexia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive 1 of 2 doses of Megace oral suspension daily for 24\n      weeks; at 12 weeks, those receiving the lower dose who have not gained 5 pounds over\n      baseline or had appetite improvement to good or excellent are escalated to the higher dose.\n      Patients are evaluated at 4-week intervals. Dose may be adjusted to maintain a desired\n      weight."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patient must have:\n\n          -  HIV infection.\n\n          -  Evidence of HIV wasting syndrome that includes anorexia (appetite fair or poor) and\n             weight loss >= 10 percent of pre-illness body weight.\n\n          -  Perception of weight loss as a detriment.\n\n          -  Life expectancy of at least 24 weeks.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Megestrol acetate for weight gain at a dose < 400 mg for < 60 days, provided therapy\n             was discontinued at least 3 months prior to study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Poorly controlled hypertension.\n\n          -  Heart failure.\n\n          -  Deep vein thrombosis.\n\n          -  Uncontrolled severe diarrhea.\n\n          -  Treatable active current infection (excluding chronic low-grade opportunistic\n             infections).\n\n          -  Unable to intake food.\n\n          -  Impaired digestive/absorptive function.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Initiation during the study of any therapy to treat HIV or anorexia/cachexia (other\n             than study drug).\n\n        Patients with the following prior conditions are excluded:\n\n          -  Hospitalization for or exacerbation of illness associated with weight loss within the\n             past 2 weeks.\n\n          -  Participation in other investigational drug studies within the past month.\n\n          -  Previous abnormal mammogram (if 35-40 years of age) or abnormal mammogram within the\n             past year (if over 40 years of age).\n\n        Prior Medication:\n\n        Excluded:\n\n          -  New antiviral therapy within the past 8 weeks.\n\n          -  Medications to promote weight gain (e.g., corticosteroid, dronabinol) within the past\n             2 months.\n\n          -  Megestrol acetate within the past 3 months. IV drug abuse not treated for at least 4\n             months."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 2, 1999", 
        "id_info": {
            "nct_id": "NCT00002345", 
            "org_study_id": "025C", 
            "secondary_id": "MEG169-93.007"
        }, 
        "intervention": {
            "intervention_name": "Megestrol acetate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Megestrol", 
                "Megestrol Acetate"
            ]
        }, 
        "keyword": [
            "Megestrol", 
            "Acquired Immunodeficiency Syndrome", 
            "Anorexia", 
            "Cachexia", 
            "Suspensions"
        ], 
        "lastchanged_date": "October 1, 2007", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "Univ of California - Davis Med Ctr / CARES"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "065102483"
                    }, 
                    "name": "Yale Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "200072197"
                    }, 
                    "name": "Georgetown Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02906"
                    }, 
                    "name": "Miriam Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002345"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {
        "Georgetown Univ Med Ctr": "38.895 -77.036", 
        "Miriam Hosp": "41.824 -71.413", 
        "Univ of California - Davis Med Ctr / CARES": "38.582 -121.494", 
        "Yale Univ Med School": "41.308 -72.928"
    }
}